Germany Pharmaceuticals and Healthcare Report Q4 2016

Publisher Name :
Date: 14-Sep-2016
No. of pages: 102

BMI View: Germany's large and expanding pharmaceutical market will continue to generate commercial

opportunities for drugmakers over the forecast period. While Germany's ongoing economic rebalancing

will continue to support robust domestic consumption indices, including in health sector segments,

healthcare spending will also be driven by population growth owing to net migration in the medium term.

Meanwhile, German economic resilience after the UK's EU referendum vote bodes well for the country's

healthcare and pharmaceuticals growth story. However, heightened economic and political risks will

remain a key concern for Germany, posing downside risks to our sector forecasts.

Headline Expenditure Projections

? Pharmaceuticals: EUR46.50bn (USD50.62bn) in 2015 to EUR46.98bn (USD51.68bn) in 2016; +1.0%

in local currency terms and 2.1% in US dollar terms. Forecast revised downwards in local currency

terms and upwards in US dollar terms from last quarter.

? Healthcare: EUR339.63bn (USD369.76bn) in 2015 to EUR350.32bn (USD385.35bn) in 2016; +3.2% in

local currency terms and +4.2% in US dollar terms. Forecast revised upwards from last quarter.

Germany Pharmaceuticals and Healthcare Report Q4 2016

Table of Contents

BMI Industry View 7
Table: Headline Pharmaceuticals & Healthcare Forecasts (Germany 2014-2020) 7
SWOT 9
Industry Forecast 11
Pharmaceutical Market Forecast 11
Table: Pharmaceutical Sales, Historical Data And Forecasts (Germany 2012-2020) 13
Healthcare Market Forecast 14
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Germany 2012-2020) 16
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Germany 2012-2020) 16
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Germany 2012-2020) 17
Prescription Drug Market Forecast 18
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Germany 2012-2020) 19
Table: Retail Pharmaceutical Expenditure, 2003-2010 (EURbn) 19
Table: Retail Pharmaceutical Expenditure, 2003-2010 (Packages, ms) 20
Table: Retail Pharmaceutical Expenditure, 2003-2010 (Average Price per Pack, EUR) 20
Patented Drug Market Forecast 21
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Germany 2012-2020) 23
Generic Medicine Market Forecast 24
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Germany 2012-2020) 26
OTC Medicines Market Forecast 27
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Germany 2012-2020) 28
Pharmaceutical Trade Forecast 29
Table: Pharmaceutical Trade Data And Forecasts (Germany 2014-2020) 30
Table: Pharmaceutical Trade Data And Forecasts local currency (Germany 2014-2020) 31
Pharmaceuticals Risk/Reward Index 32
Western Europe Risk/Reward Index 32
Germany Risk/Reward Index 38
Rewards 38
Risks 38
Regulatory Review 40
Intellectual Property Regime 42
Pricing Regime 43
Reimbursement Regime 46
Market Overview 48
Healthcare Sector 49
Table: Healthcare Resources (Germany 2010-2015) 51
Table: Healthcare Personnel (Germany 2010-2015) 52
Table: Healthcare Activity (Germany 2010-2015) 52
Research & Development 52
Clinical Trials 58
Epidemiology 59
Competitive Landscape 62
Research-Based Industry 62
Table: Multinational Market Activity 64
Pharmaceutical Distribution 65
Pharmaceutical Retail Sector 65
Company Profile 67
Bayer Health Care 67
Boehringer Ingelheim 72
GlaxoSmithKline (GSK) 77
Merck KGaA 80
Pfizer 84
STADA Arzneimittel 87
Demographic Forecast 91
Demographic Outlook 91
Table: Population Headline Indicators (Germany 1990-2025) 92
Table: Key Population Ratios (Germany 1990-2025) 92
Table: Urban/Rural Population & Life Expectancy (Germany 1990-2025) 93
Table: Population By Age Group (Germany 1990-2025) 93
Table: Population By Age Group % (Germany 1990-2025) 94
Glossary 96
Methodology 98
Pharmaceutical Expenditure Forecast Model 98
Healthcare Expenditure Forecast Model 98
Notes On Methodology 99
Risk/Reward Index Methodology 100
Index Overview 101
Table: Pharmaceutical Risk/Reward Index Indicators 101
Indicator Weightings 102

List of Tables

Table: Headline Pharmaceuticals & Healthcare Forecasts (Germany 2014-2020)
Table: Pharmaceutical Sales, Historical Data And Forecasts (Germany 2012-2020)
Table: Healthcare Expenditure Trends, Historical Data And Forecasts (Germany 2012-2020)
Table: Government Healthcare Expenditure Trends, Historical Data And Forecasts (Germany 2012-2020)
Table: Private Healthcare Expenditure Trends, Historical Data And Forecasts (Germany 2012-2020)
Table: Prescription Drug Market Indicators, Historical Data And Forecasts (Germany 2012-2020)
Table: Retail Pharmaceutical Expenditure, 2003-2010 (EURbn)
Table: Retail Pharmaceutical Expenditure, 2003-2010 (Packages, ms)
Table: Retail Pharmaceutical Expenditure, 2003-2010 (Average Price per Pack, EUR)
Table: Patented Drug Market Indicators, Historical Data And Forecasts (Germany 2012-2020)
Table: Generic Drug Market Indicators, Historical Data And Forecasts (Germany 2012-2020)
Table: Over-The-Counter (OTC) Medicine Market Indicators, Historical Data And Forecasts (Germany 2012-2020)
Table: Pharmaceutical Trade Data And Forecasts (Germany 2014-2020)
Table: Pharmaceutical Trade Data And Forecasts local currency (Germany 2014-2020)
Table: Healthcare Resources (Germany 2010-2015)
Table: Healthcare Personnel (Germany 2010-2015)
Table: Healthcare Activity (Germany 2010-2015)
Table: Multinational Market Activity
Table: Population Headline Indicators (Germany 1990-2025)
Table: Key Population Ratios (Germany 1990-2025)
Table: Urban/Rural Population & Life Expectancy (Germany 1990-2025)
Table: Population By Age Group (Germany 1990-2025)
Table: Population By Age Group % (Germany 1990-2025)
Table: Pharmaceutical Risk/Reward Index Indicators
  • Healthy Diet Demand In Developed Economies To Boost Nutraceuticals
    As customers scuffle to keep up with the frantic lifestyles, the necessity for healthy nutrition rises owing to dearth of time to spend on laborious exercises.  Customers are shifting their attention to swift and healthy food behaviours. Increase in intake of beverages and functional food has offered makers of nutraceuticals with money-spinning prospects to benefit [...]
  • World Economic Forum Unveils Top 10 Emerging Technologies of 2016
    The World Economic Forum (WEF) and Scientific American lately unveiled the major technological innovation list of the top ten emerging technologies of 2016. This list emphasizes on the technological developments which have the supremacy to transform industries, protect the planet, and improve lives. It also presents an opening to discuss any societal, human, economic or [...]
  • Siemens Adds To the Growth of Wind Power Generation Market
    Siemens has been presenting ground-breaking strategies and pioneering solutions for energy generation for an intelligent power supply globally. With an expansive portfolio and wide-ranging proficiency in wind power generation, Siemens is likely to aid in increasing the share of wind power in the US energy mix. With New Mexico’s vicinity to significant wind energy areas, [...]
  • Global Public Safety LTE Ecosystem Overview
    In view of its flourishing ecosystem, spectrum flexibility and performance metrics, LTE has emerged as the leading candidate for public safety mobile broadband networks. Public safety organizations and establishments have already begun planning to advance their networks to LTE-based public safety solutions. LTE provisions a varied range of services, from high bandwidth data services to [...]
  • RnR Market Research: Biochips Market Insights
    Growing R&D investment and subcontracting of pharmaceutical companies would lead to growth in biochips market in Asia along with an increase in the application of biochips products is estimated to improve opportunity for the global biochip market. Conversely, the high cost involved in manufacturing of biochips can be seen as a challenge for the same. [...]
  • Croatia Pharmaceuticals and Healthcare Report Q4 2016
    Published: 28-Sep-2016        Price: US 1295 Onwards        Pages: 78
    BMI View: Continued political instability coupled with a bleak economic outlook will continue to repress the pharmaceutical and healthcare sectors in Croatia. Necessary austerity measures will impose further barriers towards growth and reduce the use of high-value patented drugs, highlighting minimal revenue earning opportunities for multinational pharmaceutical firms. Headline Expenditure Projections ? Pharmaceuticals: HRK6.73bn (USD860mn) in 2015 to HRK6.70bn (USD......
  • Hungary Pharmaceuticals and Healthcare Report Q4 2016
    Published: 28-Sep-2016        Price: US 1295 Onwards        Pages: 83
    BMI View: The Hungarian government's fiscal stimulus initiatives will boost the private consumption of pharmaceuticals, particularly the over the counter medicines segment. A secondary set of initiatives are aimed at increasing domestic production capabilities, such as the pharmaceutical sector. While this will increase competition in the slow-growth domestic medicine market, it may lead to increased incentives for manufacturers to locate manufacturing facilities in the c......
  • Iran Pharmaceuticals and Healthcare Report Q4 2016
    Published: 28-Sep-2016        Price: US 1295 Onwards        Pages: 98
    BMI View: The removal of economic sanctions heralds an era of uncertainty for Iran's pharmaceutical market. Underlying issues regarding the operating environment will prevent an immediate uptick in multinational drugmaker interest; rather, this will be a gradual process. Nevertheless, there has been a notable boost in international cooperation with European counterparts in particular over the past six months. This will support the Iranian government's aim to attract great......
  • Ireland Pharmaceuticals and Healthcare Report Q4 2016
    Published: 28-Sep-2016        Price: US 1295 Onwards        Pages: 75
    BMI View: The Irish government's four-year agreement with the pharmaceutical industry with regard to drug pricing reflects the government's continued focus on cost control measures targeting pharmaceutical expenditure. The agreed price-reduction mechanism for existing medicines will, however, allow for the prioritisation of funding toward ensuring access to new, innovative medicines. While the pharmaceutical market will continue to decline in value terms, Ireland's robust......
  • Australia Pharmaceuticals and Healthcare Report Q4 2016
    Published: 28-Sep-2016        Price: US 1295 Onwards        Pages: 98
    BMI View: The incumbent Liberal-National coalition's victory in Australia's federal elections will not bring about a clear policy direction for the healthcare sector. While the government has a fresh mandate to enact its policies, it is considerably weaker from the previous election and will be constrained by senate politics where the coalition does not have a majority. This creates downside risks for pharmaceutical firms keen to see promises by the coalition, such as an ......
  • Iraq Pharmaceuticals and Healthcare Report Q4 2016
    Published: 21-Sep-2016        Price: US 1295 Onwards        Pages: 68
    BMI View: Iraq's ailing domestic landscape will dampen investor confidence in the country's pharmaceuticals and healthcare sectors over at least the next few years if not longer. Although the government remains committed to healthcare provision, economic and security headwinds will mean international support will remain key to ensuring the population's access to healthcare. Indeed, the domestic sector's capabilities will remain limited for the foreseeable future. The Iraq......
  • Oman Pharmaceuticals and Healthcare Report Q4 2016
    Published: 21-Sep-2016        Price: US 1295 Onwards        Pages: 75
    BMI View: The Oman Ministry of Health's decision to postpone the latest phase of medicine price reductions highlights the opaque nature of the country's pharmaceutical sector. Over the long term, Oman's population will benefit from more affordable healthcare services as even more medicines are reduced in price, however the impact on drugmaker's profit margins will continue to come under question. Nonetheless, Oman's evolving demographic and epidemiological profile will ac......
  • Pakistan Pharmaceuticals and Healthcare Report Q4 2016
    Published: 21-Sep-2016        Price: US 1295 Onwards        Pages: 108
    BMI View: Pakistan's pharmaceutical market will remain a low priority for innovative drugmakers. Downward price pressures on pharmaceutical prices coupled with uncertainty surrounding the country's policy direction impinge on potential commercial opportunities, while a fragmented procurement system hinders efforts to establish sales strategy. These factors result in an unattractive medicines market that will incentivise multinational pharmaceutical firms to invest in othe......
  • Puerto Rico Pharmaceuticals and Healthcare Report Q4 2016
    Published: 21-Sep-2016        Price: US 1295 Onwards        Pages: 91
    BMI View: An expected increase in US government funding to strengthen Puerto Rico's healthcare system will support pharmaceutical and healthcare sector growth in the commonwealth over the next few years. While the US administration will continue to seek legislative removal of Puerto Rico's Medicaid funding limitations over the coming months, the increasing risk posed by the Zika virus outbreak in the territory will push for a rise in healthcare funding to become a priorit......
  • SERVICES
    Value for Money
    We believe in "optimum utilization of available budget and resources". While servicing our clients' (your) market research requirements, we keep the same approach in focus to help you get the best value for your $$s.
    Ever Growing Inventory
    Ranging from the smallest feasible / required data (datasheets, data facts, SWOT analysis, company profiles, etc) to full research reports that help you make decisions, our inventory is updated almost on a daily basis with the latest industry reports from domain experts that track more than 5000 niche sectors.
    One Stop Solution
    Need a custom research report on medical devices market? Require all available business intelligence on 3D printing industry? Exploring F&B sector of a particular country/region? RnRMarketResearch.com is your one-stop-solution to all market intelligence needs. We not only offer custom research and consulting services, we also "bundle" reports to meet your needs and help you fetch the data analysis you require for your business.
    Dedicated Client Engagement
    Not limited to only "finding" relevant reports for you, our client engagement team dedicates its efforts to understand your "business need" and accordingly maps available research data to help you move forward. Call "your" client engagement executive any time of your day and get your questions answered in order to make the correct business decision.
    Saving Time and Efforts
    Simply share your research requirement details with us and let us do all the hard work to find required intelligence for you. When you add up our "one stop solution" and "dedicated client engagement" services mentioned above, you obviously know the time and effort saving you do by working with us.
    Payment Flexibility
    Working with Fortune 500 organizations, we understand the importance of being flexible for payments. Share your payment terms with us and we will surely match up to them to ensure you get access to required business intelligence data without having to wait for the payment to be done.
    Post-Purchase Research Support
    Have questions after reading a report / datasheet bought through us? Not sure about the methodology used for data available in the research? Talk to us / Share your questions with us and if required, we will connect you with the analyst(s)/author(s) of the report(s) and ensure you get satisfactory answers for the same. Need more data / analysis / report(s) on the topic of your research/project? The RnRMarketResearch.com team is here for you 24X7 to support you with your post-purchase requirements. Subscription Offers & Packages (Get in touch with us for more details - sales@rnrmarketresearch.com / +1 888 391 5441 )
    • Ad Hoc
    • Pay - as - you - go / Bucket Subscriptions
    • Fixed Cost for #of reports
    • Customize / Personalize as per your needs